Prior to examination of the above-identified new national phase patent application, please amend the application, as follows:

In the Specification

Please insert on page 1, between the title of the application and the first paragraph, the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U. S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02589 filed August 2, 2000, which in turn claims priority of German Patent Application No. 199 37 264.0 filed August 6, 1999.

In the Claims

Please amend claims 1-12 and 14 to read as follows:

1. A F_V antibody construct having binding sites for an CDl6 receptor and a CD3O surface protein.

2. The F_v antibody construct according to claim 1, wherein the CD16 receptor is derived from NK cells.

3. The F_V antibody construct according to claim 1, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

4. The F_V antibody construct according to claim 1, wherein one binding site is present each.

5. The F_V antibody construct according to claim 4, encoded by the expression vector pKTDl6-30 (DEM 12960).

6. The F_V antibody construct according to claim 1, wherein two binding sites are present for

each.

7. An expression vector, coding for the F_V antibody construct according to claim 1.

8. The expression vector according to claim 7, which is pKID16-30 (DSM 12960).

9. A transformant, containing the expression vector according to claim 7.

10. A method of producing the Fv antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.

11. A kit comprising:

(a) an F_V antibody construct according to the invention

and/or

(b) an expression vector according to the invention, and

(c) common auxiliary substances, such as buffers, solvents, carriers, controls and markers,

wherein one or more representatives of the individual components may be present.

12. Use of the F_V antibody construct according to claim 1 for lysis of cells expressing CD30 surface proteins.

14. Use according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

Please add claims 15-18.

15. The F_V antibody construct according to claim 2, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

16. An expression vector, coding for the F_V antibody construct according to claim 15.